Mallmann P
Department of Gynecology and Obstetrics, University of Bonn, Germany.
Hybridoma. 1995 Apr;14(2):187-90. doi: 10.1089/hyb.1995.14.187.
Tumor vaccination is a form of an active specific immunotherapy that aims in the induction of a specific immune response against the tumor. In the last 30 years a great number of studies had been performed using native, not modified tumor cells or different methods of modifying tumor cells. In the last year viral xenogenization of tumor cells had been extensively examined in different studies. In gynecologic cancer patients it could be demonstrated that in a certain part of vaccinated patients an increase of specific cytotoxicity could be induced and that compared with historic controls, a benefit in ovarian cancer patients could be observed. There are further results showing that a pretreatment of tumor-bearing hosts prior to vaccination may enhance subsequent immune reactivity and enhance the susceptibility of tumor cells. This is the rationale of a combination of chemo- and immunotherapy.
肿瘤疫苗接种是一种主动特异性免疫疗法,旨在诱导针对肿瘤的特异性免疫反应。在过去30年里,人们使用天然的、未修饰的肿瘤细胞或不同的肿瘤细胞修饰方法进行了大量研究。去年,肿瘤细胞的病毒异种移植在不同研究中得到了广泛研究。在妇科癌症患者中,可以证明在一定比例的接种患者中可诱导特异性细胞毒性增加,并且与历史对照相比,可观察到卵巢癌患者有获益。还有进一步的结果表明,在接种疫苗前对荷瘤宿主进行预处理可能会增强随后的免疫反应性,并提高肿瘤细胞的敏感性。这就是化疗和免疫疗法联合使用的理论基础。